Kilitch Drugs(I) Ltd

Kilitch Drugs(I) Annual General Meeting

Kilitch Drugs (India) held its 34th Annual General Meeting on August 27, 2026, transacting four business resolutions including financial statement approval and director re-appointment.

Kilitch Drugs(I) Other Announcement

Kilitch Drugs filed its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Rights Issue proceeds of Rs. 49.92 Crore.

Value

₹49.92 Cr

Kilitch Drugs(I) Q1 FY27 Results: Net Profit ₹2 Cr, Down 13.0% YoY

Kilitch Drugs(I) Ltd reported revenue from operations of ₹44.9 Cr (+4.2% YoY) and net profit of ₹2 Cr (-13.0% YoY) for Q1 FY27.

Key figure

Net profit ₹2 Cr · -13.0% YoY

Kilitch Drugs(I) Board Meeting Date

Kilitch Drugs (India) Ltd has scheduled a board meeting for August 13, 2026. The board will consider and approve unaudited financial results for the June quarter.

Kilitch Drugs(I) Annual Report

Kilitch Drugs submitted its Annual Report for FY 2025-26 and the notice for the 34th Annual General Meeting to the stock exchanges.

Kilitch Drugs(I) Management Change

Kilitch Drugs (India) Limited has re-appointed Arivind Kumar & Co. as its Cost Auditor for a 12-month term.

Kilitch Drugs(I) Annual General Meeting

Kilitch Drugs (India) Ltd announced its 34th Annual General Meeting scheduled for August 27, 2026, along with relevant book closure dates. The board also re-appointed cost auditors.